Fiduciary Group LLC lowered its stake in AbbVie Inc (NYSE:ABBV) by 8.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 61,508 shares of the company’s stock after selling 5,745 shares during the quarter. AbbVie comprises 1.2% of Fiduciary Group LLC’s portfolio, making the stock its 29th largest position. Fiduciary Group LLC’s holdings in AbbVie were worth $5,466,000 as of its most recent filing with the SEC.
Several other hedge funds also recently bought and sold shares of the company. Hudock Capital Group LLC boosted its holdings in AbbVie by 109.5% in the second quarter. Hudock Capital Group LLC now owns 1,542 shares of the company’s stock valued at $111,000 after purchasing an additional 806 shares during the last quarter. Ffcm LLC boosted its holdings in AbbVie by 167.2% in the second quarter. Ffcm LLC now owns 1,539 shares of the company’s stock valued at $111,000 after purchasing an additional 963 shares during the last quarter. Bristlecone Advisors LLC purchased a new position in AbbVie in the third quarter valued at about $113,000. BDO Wealth Advisors LLC purchased a new position in AbbVie in the second quarter valued at about $115,000. Finally, Hershey Trust Co. purchased a new position in AbbVie in the third quarter valued at about $139,000. Institutional investors and hedge funds own 69.54% of the company’s stock.
A number of research analysts recently commented on ABBV shares. Jefferies Group increased their price target on AbbVie from $107.00 to $115.00 and gave the company a “buy” rating in a report on Monday, October 16th. BMO Capital Markets set a $66.00 price target on AbbVie and gave the company a “hold” rating in a report on Friday, October 27th. BidaskClub raised AbbVie from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 11th. Piper Jaffray Companies increased their price target on AbbVie to $115.00 and gave the company an “overweight” rating in a report on Friday, October 27th. Finally, SunTrust Banks reissued a “buy” rating on shares of AbbVie in a report on Monday, October 30th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. AbbVie has a consensus rating of “Buy” and a consensus target price of $117.26.
AbbVie Inc (ABBV) opened at $111.30 on Friday. The company has a current ratio of 1.45, a quick ratio of 1.32 and a debt-to-equity ratio of 5.08. AbbVie Inc has a 1-year low of $60.15 and a 1-year high of $125.86. The company has a market capitalization of $173,180.72, a P/E ratio of 33.83, a price-to-earnings-growth ratio of 1.03 and a beta of 1.60.
AbbVie (NYSE:ABBV) last released its earnings results on Friday, January 26th. The company reported $1.48 EPS for the quarter, topping analysts’ consensus estimates of $1.44 by $0.04. AbbVie had a return on equity of 152.78% and a net margin of 18.82%. The company had revenue of $7.74 billion for the quarter, compared to the consensus estimate of $7.53 billion. During the same quarter last year, the business posted $1.20 EPS. AbbVie’s quarterly revenue was up 13.9% compared to the same quarter last year. sell-side analysts expect that AbbVie Inc will post 7.46 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Fiduciary Group LLC Sells 5,745 Shares of AbbVie Inc (ABBV)” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://sportsperspectives.com/2018/02/10/fiduciary-group-llc-sells-5745-shares-of-abbvie-inc-abbv.html.
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.